Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.

Joshua J. Field, Gene Lin, Maureen M. Okam, Elaine Majerus, Jeffrey Keefer, Onyinye Onyekwere, Ainsley Ross, Federico Campigotto, Donna Neuberg, Joel Linden, David G. Nathan

Research output: Contribution to journalArticle

Abstract

Adenosine A2A receptor (A2AR) agonists reduce invariant natural killer T (iNKT) cell activation and decrease inflammation in sickle cell disease (SCD) mice. We conducted a phase 1 trial of the A2AR agonist regadenoson in adults with SCD. The target dose was 1.44 μg/kg/h. iNKT cell activation was evaluated using antibodies targeting the p65 subunit of nuclear factor-κB (phospho-NF-κB p65), interferon-γ (IFN-γ), and A2AR. Regadenoson was administered to 27 adults with SCD. We examined 21 patients at steady state and 6 during painful vaso-occlusive crises (pVOC). iNKT cell activation was also measured in 14 African-American controls. During pVOC, the fraction of iNKT cells demonstrating increased phospho-NF-κB p65 and A2AR expression was significantly higher compared with controls (P <.01) and steady-state patients (P <.05). IFN-γ expression was also significantly higher compared with controls (P = .02). After a 24-hour infusion of regadenoson during pVOC, phospho-NF-κB p65 activation in iNKT cells decreased compared to baseline by a median of 48% (P = .03) to levels similar to controls and steady-state SCD. No toxicities were identified. Infusional regadenoson administered to adults with SCD at 1.44 μg/kg/h during pVOC decreases activation of iNKT cells without toxicity.

Original languageEnglish (US)
Pages (from-to)3329-3334
Number of pages6
JournalBlood
Volume121
Issue number17
DOIs
StatePublished - Apr 25 2013

Fingerprint

Adenosine A2 Receptor Agonists
Natural Killer T-Cells
T-cells
Sickle Cell Anemia
Chemical activation
Interferons
Toxicity
Interferon Receptors
African Americans
regadenoson
Inflammation
Antibodies

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. / Field, Joshua J.; Lin, Gene; Okam, Maureen M.; Majerus, Elaine; Keefer, Jeffrey; Onyekwere, Onyinye; Ross, Ainsley; Campigotto, Federico; Neuberg, Donna; Linden, Joel; Nathan, David G.

In: Blood, Vol. 121, No. 17, 25.04.2013, p. 3329-3334.

Research output: Contribution to journalArticle

Field, JJ, Lin, G, Okam, MM, Majerus, E, Keefer, J, Onyekwere, O, Ross, A, Campigotto, F, Neuberg, D, Linden, J & Nathan, DG 2013, 'Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.', Blood, vol. 121, no. 17, pp. 3329-3334. https://doi.org/10.1182/blood-2012-11-465963
Field, Joshua J. ; Lin, Gene ; Okam, Maureen M. ; Majerus, Elaine ; Keefer, Jeffrey ; Onyekwere, Onyinye ; Ross, Ainsley ; Campigotto, Federico ; Neuberg, Donna ; Linden, Joel ; Nathan, David G. / Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. In: Blood. 2013 ; Vol. 121, No. 17. pp. 3329-3334.
@article{c5b5b3daa5374338bcf698da48286bd7,
title = "Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.",
abstract = "Adenosine A2A receptor (A2AR) agonists reduce invariant natural killer T (iNKT) cell activation and decrease inflammation in sickle cell disease (SCD) mice. We conducted a phase 1 trial of the A2AR agonist regadenoson in adults with SCD. The target dose was 1.44 μg/kg/h. iNKT cell activation was evaluated using antibodies targeting the p65 subunit of nuclear factor-κB (phospho-NF-κB p65), interferon-γ (IFN-γ), and A2AR. Regadenoson was administered to 27 adults with SCD. We examined 21 patients at steady state and 6 during painful vaso-occlusive crises (pVOC). iNKT cell activation was also measured in 14 African-American controls. During pVOC, the fraction of iNKT cells demonstrating increased phospho-NF-κB p65 and A2AR expression was significantly higher compared with controls (P <.01) and steady-state patients (P <.05). IFN-γ expression was also significantly higher compared with controls (P = .02). After a 24-hour infusion of regadenoson during pVOC, phospho-NF-κB p65 activation in iNKT cells decreased compared to baseline by a median of 48{\%} (P = .03) to levels similar to controls and steady-state SCD. No toxicities were identified. Infusional regadenoson administered to adults with SCD at 1.44 μg/kg/h during pVOC decreases activation of iNKT cells without toxicity.",
author = "Field, {Joshua J.} and Gene Lin and Okam, {Maureen M.} and Elaine Majerus and Jeffrey Keefer and Onyinye Onyekwere and Ainsley Ross and Federico Campigotto and Donna Neuberg and Joel Linden and Nathan, {David G.}",
year = "2013",
month = "4",
day = "25",
doi = "10.1182/blood-2012-11-465963",
language = "English (US)",
volume = "121",
pages = "3329--3334",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "17",

}

TY - JOUR

T1 - Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.

AU - Field, Joshua J.

AU - Lin, Gene

AU - Okam, Maureen M.

AU - Majerus, Elaine

AU - Keefer, Jeffrey

AU - Onyekwere, Onyinye

AU - Ross, Ainsley

AU - Campigotto, Federico

AU - Neuberg, Donna

AU - Linden, Joel

AU - Nathan, David G.

PY - 2013/4/25

Y1 - 2013/4/25

N2 - Adenosine A2A receptor (A2AR) agonists reduce invariant natural killer T (iNKT) cell activation and decrease inflammation in sickle cell disease (SCD) mice. We conducted a phase 1 trial of the A2AR agonist regadenoson in adults with SCD. The target dose was 1.44 μg/kg/h. iNKT cell activation was evaluated using antibodies targeting the p65 subunit of nuclear factor-κB (phospho-NF-κB p65), interferon-γ (IFN-γ), and A2AR. Regadenoson was administered to 27 adults with SCD. We examined 21 patients at steady state and 6 during painful vaso-occlusive crises (pVOC). iNKT cell activation was also measured in 14 African-American controls. During pVOC, the fraction of iNKT cells demonstrating increased phospho-NF-κB p65 and A2AR expression was significantly higher compared with controls (P <.01) and steady-state patients (P <.05). IFN-γ expression was also significantly higher compared with controls (P = .02). After a 24-hour infusion of regadenoson during pVOC, phospho-NF-κB p65 activation in iNKT cells decreased compared to baseline by a median of 48% (P = .03) to levels similar to controls and steady-state SCD. No toxicities were identified. Infusional regadenoson administered to adults with SCD at 1.44 μg/kg/h during pVOC decreases activation of iNKT cells without toxicity.

AB - Adenosine A2A receptor (A2AR) agonists reduce invariant natural killer T (iNKT) cell activation and decrease inflammation in sickle cell disease (SCD) mice. We conducted a phase 1 trial of the A2AR agonist regadenoson in adults with SCD. The target dose was 1.44 μg/kg/h. iNKT cell activation was evaluated using antibodies targeting the p65 subunit of nuclear factor-κB (phospho-NF-κB p65), interferon-γ (IFN-γ), and A2AR. Regadenoson was administered to 27 adults with SCD. We examined 21 patients at steady state and 6 during painful vaso-occlusive crises (pVOC). iNKT cell activation was also measured in 14 African-American controls. During pVOC, the fraction of iNKT cells demonstrating increased phospho-NF-κB p65 and A2AR expression was significantly higher compared with controls (P <.01) and steady-state patients (P <.05). IFN-γ expression was also significantly higher compared with controls (P = .02). After a 24-hour infusion of regadenoson during pVOC, phospho-NF-κB p65 activation in iNKT cells decreased compared to baseline by a median of 48% (P = .03) to levels similar to controls and steady-state SCD. No toxicities were identified. Infusional regadenoson administered to adults with SCD at 1.44 μg/kg/h during pVOC decreases activation of iNKT cells without toxicity.

UR - http://www.scopus.com/inward/record.url?scp=84879350342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879350342&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-11-465963

DO - 10.1182/blood-2012-11-465963

M3 - Article

VL - 121

SP - 3329

EP - 3334

JO - Blood

JF - Blood

SN - 0006-4971

IS - 17

ER -